MENINGOCOCCAL ANTIGENS (MA): A NOVEL IMMUNE STIMULANT IN EXPERIMENTAL NEOPLASIA

Authors
  1. Teodorczyk-Injeyan, J.A.
  2. Sparkes, B.G.
  3. Dupuy, J.M.
  4. and others
Corporate Authors
Defence and Civil Inst of Environmental Medicine, Downsview ONT (CAN);Toronto Univ, Toronto ONT (CAN) Dept of Surgery
Abstract
An extract of the meningococcus antigens (MA) prepared from N. meningitidis was tested for an anti-tumor effect in rat and murine metastasizing tumor models. Effectiveness of MA in each model varied with dose and was manifested as significantly improved survival of the treated animals. Growth of the primary Fischer bladder carcinoma (FBCa) and metastases to lungs and lymph nodes were significantly inhibited in F344-rats treated weekly with 1 mg MA. Administration of MA at 100 mu g per animal significantly prolonged survival of P815 mastocytoma-inoculated DBA/2 mice. Survival of C-26 colon adenocarinoma-bearing Balb/c mice was significantly improved in animals that received weekly injections of 20 mu g MA, without significant effect on the developmnt of local tumor. The meningococcal antigens demonstrate strong mitogenic activity in B-cell enriched murine spleen cultures. TRUNCATED
Report Number
83-P-40 — Research Paper
Date of publication
01 Jan 1983
Number of Pages
4
Reprinted from
Cancer Immunol Immunother, vol 15, 1983, p 217-220
DSTKIM No
84-02544
CANDIS No
121927
Format(s):
Originator's fiche received by DSIS;Hardcopy

Permanent link

Document 1 of 1

Date modified: